How to Help Your Patients Save Money on Januvia: A Provider's Guide to Savings Programs

Januvia (sitagliptin) costs $600–$700 per month without insurance — and even insured patients can face significant copays, prior authorization hurdles, and formulary restrictions. As a prescriber, knowing the available savings options for Januvia allows you to proactively reduce cost barriers at the point of care, improve medication adherence, and maintain better glycemic outcomes for your patients.

This guide covers every savings lever available in 2026, organized by patient insurance status.

For Commercially Insured Patients: Merck Copay Savings Card

The Merck Januvia savings card is the most impactful tool for privately insured patients with high copays. Key details:

Benefit: Patient pays as little as $5 per prescription; Merck covers up to $150 per qualifying fill

Supply: Valid for up to a 90-day supply per prescription fill

Frequency: Redeemable once every 30 days

Eligibility: Patients with commercial (private) insurance ONLY — NOT valid for Medicare, Medicaid, Tricare, VA, CHIP, or other government insurance

Cannot combine: Not combinable with GoodRx, SingleCare, or other discount savings programs

Where to access: januvia.com or provide a printed coupon from your office. You can also request that Merck representatives bring cards to your practice.

Clinical tip: At the time of prescribing, proactively ask patients with commercial insurance whether they have the Merck savings card. Many patients are unaware it exists.

For Uninsured and Underinsured Patients: Merck Patient Assistance Program

The Merck Patient Assistance Program (merckhelps.com) provides Januvia free of charge to qualifying uninsured and low-income patients. This program is particularly important as Januvia remains brand-name-only with no true widely available generic in 2026.

Eligibility: Based on income and insurance status; Merck reviews applications individually

Duration: Free medication for up to 1 year; patients can reapply annually

Provider role: Your office must complete a portion of the application form. Plan 15–30 minutes of staff time for the initial enrollment.

Contact: merckhelps.com or call 1-800-727-5400

Clinical tip: Use Merck samples to bridge patients while PAP paperwork is processed (typically 1–4 weeks). Request samples through the Merck Sample Portal.

For Medicare and Medicaid Patients: Limited Options — Here's What Helps

Government insurance beneficiaries are not eligible for the Merck copay savings card. Options for Medicare and Medicaid patients include:

Medicare Extra Help (Low Income Subsidy): Eligible Medicare Part D beneficiaries with limited income and resources can get significantly reduced drug costs. Refer to SSA.gov or have your social worker assist with application.

Merck Patient Assistance Program: Some Medicare patients with income below program thresholds may still qualify for PAP assistance.

Prescribe Zituvio instead: Zituvio (sitagliptin free base, Zydus) is FDA-approved for type 2 diabetes, contains the same active ingredient as Januvia, and may have different formulary tier placement or GoodRx pricing (~$110/month at select pharmacies). Requires a new Rx.

Consider generic alternatives: Generic saxagliptin and alogliptin are DPP-4 inhibitors with Medicare Part D coverage typically at lower tiers. Confirm cardiovascular suitability first (heart failure warning).

Discount Cards — Useful for All Patients Without Active Manufacturer Programs

Free discount cards can significantly reduce Januvia's cost for patients who aren't eligible for manufacturer programs, don't want to use their insurance (e.g., patients with high deductibles or HSA accounts), or are waiting for PAP enrollment to be processed:

GoodRx (goodrx.com/januvia): Significant reduction vs. retail for brand Januvia; generic sitagliptin (Zituvio/authorized) as low as $110 at select pharmacies

SingleCare (singlecare.com): Typically $285–$286 for 30 tablets of Januvia 100 mg at participating pharmacies

Rx savings apps (Blink Health, HealthWarehouse): Additional options worth comparing; prices vary by pharmacy and location

Prescribing tip: Consider printing or bookmarking a QR code to GoodRx.com/januvia for your waiting room or patient portal. A simple handout can save patients hours of searching.

Merck Samples — Bridge Gaps and Reduce Abandonment

Medication samples serve as a critical bridge in several clinical scenarios:

Patient awaiting prior authorization approval (typically 3–14 business days)

Patient completing Merck PAP application (typically 1–4 weeks)

New patients starting Januvia to see if they tolerate it before committing to a full prescription

Request samples through the Merck Sample Portal. Your Merck representative can also deliver samples directly to your practice on a regular schedule.

Cost-Effective Prescribing Alternatives to Januvia

When cost is the primary barrier and alternatives are clinically appropriate, consider these cost-effective options within or adjacent to the DPP-4 class:

Generic saxagliptin (previously Onglyza): DPP-4 inhibitor; significantly lower cost as generic; avoid in HF patients

Generic alogliptin (previously Nesina): DPP-4 inhibitor; low cost; similar HF signal to saxagliptin

Zituvio (sitagliptin free base): Same active ingredient as Januvia; ~$80–$110/month; requires new Rx; not interchangeable with Januvia

Generic metformin + lower-cost DPP-4: Metformin ~$4–$10/month; paired with generic saxagliptin or alogliptin offers effective, affordable dual therapy

Looking Ahead: Generic Sitagliptin in 2026

Merck's key sitagliptin phosphate patent expires November 24, 2026. Settlement agreements may allow generic entry as early as May 2026. Once widely available, generic sitagliptin is expected to cost approximately $50–$100/month — an 80–85% reduction from current retail price. Formulary tiers will likely shift to Tier 1–2, and prior authorization requirements may be lifted for many plans.

Recommendation: Inform your patients currently struggling with Januvia cost that significant relief is anticipated later in 2026. Avoid unnecessary therapy switches for patients tolerating Januvia well — the cost barrier may be temporary.

How medfinder for Providers Helps With Access (Not Just Cost)

Even when cost is managed, patients can still face availability challenges at local pharmacies. medfinder for Providers allows your team to quickly identify which pharmacies near your patient have Januvia in stock. This reduces the burden on your staff and ensures patients don't abandon their medication simply because they can't find it locally.

For a full clinical overview of Januvia access from a prescribing standpoint, see: Januvia Shortage: What Providers and Prescribers Need to Know in 2026.